NurExone Biologic Inc. filed its Annual on Mar 30, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ziv Haft, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
NurExone Biologic Inc. Toronto S.E.
Equities
ENER
CA29278Q1063
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |